Caroline Gaynor has been appointed chair of the Irish Venture Capital Association, coinciding with its 40th anniversary. She emphasised scaling indigenous start-ups and strengthening R&D investment, noting that while tariffs are unlikely to impact Irish pharmaceutical manufacturing in the short term, a two-track industrial approach is essential. Gaynor brings deep experience in biopharmaceuticals and medtech from Lightstone Ventures, aiming to drive long-term innovation and sticky foreign investment in Ireland.

Read the full article.